LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … QR-421a QR-421a is a first-in-class investigational RNAtherapy designed to address the underlying cause of vision …
… to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today … retinal degenerations, autoimmune retinopathy, and gene therapy associated uveitis. He is a principal investigator …